普瑞默立足台灣，以提供台灣人民精準醫療為宗旨，貢獻台灣醫療於分子影像領域，透過清晰可辨別的圖像，提供醫師重要資訊，這種獨特的洞察力使台灣人的醫療品質提升，全方位照顧疾病的診斷、治療、與預防。
Based in Taiwan, Primo aims to promote precision medicine for Taiwanese people with novel radiopharmaceuticals, and hopes to elevate Taiwan’s medical service quality in the prevention, diagnosis, and treatment of various diseases. Through novel radiopharmaceuticals with high specificity and sensitivity, in-vivo whole-body imaging of patients can be non-invasively provided and further used as a precision approach for physicians to increase the options available as tactics in disease management.
相較於傳統影像檢查，正子斷層掃描提供更精準的分子影像，提供醫生更多的診斷資訊，以提供更好的治療方式，尤其對於癌症腫瘤的病患而言，是一項相當重要的檢查。正子斷層造影最常使用的的藥物是放射性氟化去氧葡萄糖(F-18 FDG)，這裡提供正子斷層造影與使用F-18 FDG時會遇到的常見問題
精準藥物（Precision Medicine）的開發，尤其針對是多變且難預測的癌症，舉凡細胞治療、免疫治療與標靶治療，仍有一定的治療瓶頸。
為了使病人癌症治療效果和其治療反應的持續時間更上一層樓，因此目前亟需要一新技術以作為整體癌症醫療之再進化，不僅能夠進一步整合以上精準癌症治療方式的強項，並補強各自之弱點。而這項新技術就是目前在全球開始崛起的新治療模式，核醫放射配體診療（Radioligand Theranostics, RLT)。
Cancer immunotherapy, molecular targeted therapy, and cell therapy are major trends of precision approaches in cancer treatment and unavoidably face therapeutic bottlenecks as cancer is always changeable and unpredictable.
A new integrated technology is necessary and warranted for the facilitation of current oncologic therapeutics as a revolutionary tool for precision medicine. This relies on advanced technology to evolve cancer management, and eventually to integrate all the benefits of various cancer treatment therapies.
One primary such new technology is the globally-applicable and appealing target-specific therapeutic mode, or radioligand theranostics, also known as RLT.
